Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McGill University

$105,000.00

Predicting Rapid Progression of Interstitial Lung Disease in Systemic Sclerosis Using Pulmonary Function Tests

FY 2015-16

Summary
Systemic sclerosis is a rare and chronic autoimmune disorder affecting thousands of Canadians. It is characterized by an excess production of connective tissue resulting in thickening of the skin. In many instances, this increased fibrosis spreads to internal organs, including the heart, kidneys and lungs. Complications due to lung involvement are the leading cause of malaise and death in persons with systemic sclerosis. Lung problems in systemic sclerosis are most often characterized by interstitial lung disease. It is believed that approximately 80% to 90% of patients experience symptoms of interstitial lung disease. Most systemic sclerosis patients with interstitial lung disease undergo stable or slowly progressing pulmonary deterioration. However, certain patients experience a rapid decline in lung function, generally within the first year of disease onset. Current treatment for interstitial lung disease (including immunosuppressive therapy) is believed to prevent pulmonary deterioration rather than reverse it. For this reason, and also given the potential toxicities of these medications, therapy should be restricted to patients who are at risk of rapidly progressing lung disease as these are the individuals who would benefit most from treatment. My doctoral research will focus on predicting the progression of lung involvement in individuals with systemic sclerosis. This will then help healthcare providers identify patients with a greater risk of rapidly progressing interstitial lung disease. Measures obtained from pulmonary function tests, a non-invasive procedure that measures lung volumes, airflow rates and gas exchange, and information collected on patient-reported symptoms will be analyzed as potential predictors of interstitial lung disease progression. Ultimately, the results of this research will have a positive impact on the health of patients with systemic sclerosis.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
347956
Name
Caron Melissa
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Predicting Rapid Progression of Interstitial Lung Disease in Systemic Sclerosis Using Pulmonary Function Tests
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Epidemiology; Prediction Modeling; Pulmonary Function; Systemic Sclerosis (Scleroderma)
Abstract
Systemic sclerosis is a rare and chronic autoimmune disorder affecting thousands of Canadians. It is characterized by an excess production of connective tissue resulting in thickening of the skin. In many instances, this increased fibrosis spreads to internal organs, including the heart, kidneys and lungs. Complications due to lung involvement are the leading cause of malaise and death in persons with systemic sclerosis. Lung problems in systemic sclerosis are most often characterized by interstitial lung disease. It is believed that approximately 80% to 90% of patients experience symptoms of interstitial lung disease. Most systemic sclerosis patients with interstitial lung disease undergo stable or slowly progressing pulmonary deterioration. However, certain patients experience a rapid decline in lung function, generally within the first year of disease onset. Current treatment for interstitial lung disease (including immunosuppressive therapy) is believed to prevent pulmonary deterioration rather than reverse it. For this reason, and also given the potential toxicities of these medications, therapy should be restricted to patients who are at risk of rapidly progressing lung disease as these are the individuals who would benefit most from treatment. My doctoral research will focus on predicting the progression of lung involvement in individuals with systemic sclerosis. This will then help healthcare providers identify patients with a greater risk of rapidly progressing interstitial lung disease. Measures obtained from pulmonary function tests, a non-invasive procedure that measures lung volumes, airflow rates and gas exchange, and information collected on patient-reported symptoms will be analyzed as potential predictors of interstitial lung disease progression. Ultimately, the results of this research will have a positive impact on the health of patients with systemic sclerosis.
Competitiondate
201510
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Caron, Melissa
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McGill University - $105,000 Grant (2015-16) | Canada Spends